Showing results (101-110 of 110) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Oncotarget|March 24, 2018
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancerPhilip D Dunne, Helen G Coleman, Peter Bankhead, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2016
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)Donna Niedzwiecki, Wendy L Frankel, Alan P Venook, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2016
Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal CancerPhilip D Dunne, Darragh G McArt, Conor A Bradley, et al.Journal of the National Cancer Institute|November 15, 2007
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancerAlison M Hosey, Julia J Gorski, Margaret M Murray, et al.Gut|September 25, 2016
BCL-2 system analysis identifies high-risk colorectal cancer patientsAndreas U Lindner, Manuela Salvucci, Clare Morgan, et al.Proceedings of the National Academy of Sciences of the United States of America|July 15, 2020
The pseudo-caspase FLIP(L) regulates cell fate following p53 activationAndrea Lees, Alexander J McIntyre, Nyree T Crawford, et al.Journal of the National Cancer Institute|January 10, 2014
Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancerJude M Mulligan, Laura A Hill, Steve Deharo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2016
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal CancerManuela Salvucci, Maximilian L Würstle, Clare Morgan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2020
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal CancerSudhir B Malla, David J Fisher, Enric Domingo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissueRichard D Kennedy, Max Bylesjo, Peter Kerr, et al.Pageof 11